← Al het nieuws

VitroScan closes funding round

VitroScan, developing tests to predict treatment outcome for cancer patients, has closed a round of seed funding for €800.000. Lead investor Libertatis Ergo Holding B.V. (LEH) will be welcomed as new board member. Pieter Geelen, TomTom founder and philanthropist, and co-founder of VitroScan also provides a major part of the funds in this round. VitroScan will use the proceeds to deliver Proof of Concept for application of its unique technology for treatment response prediction for cancer patients.

Suboptimal therapy responses for patients, unnecessary side effects, and high failure rates of clinical trials with cancer drugs, cause a high burden on the health care system. This emphasises the need for better selection of treatment for the individual patient, and more efficient drug development.

VitroScan’s unique technology platform combines automated 3D cell culture with high content 3D imaging and analysis in a robust platform that provides scalability without compromising precision of drug response analysis. A clinical trial program has been initiated with leading cancer hospitals in The Netherlands to establish the value of the technology for drug response prediction in selected cancers.  

Quote LEH: “Leiden University is very excited to support VitroScan’s ambition to develop solutions and optimize treatment for cancer patients, to build on the strong technical foundation between VitroScan and Leiden University and to support entrepreneurship on the Leiden Bio Science Park.” Quote Willemijn Vader, Managing Director VitroScan: “We are excited to welcome LEH in the board of VitroScan. LEH’s expertise will facilitate collaborations with the University Medical Centers, like LUMC and the Leiden Bio Science Park Community, and will be valuable to execute our strategy and achieve our goals.” 

Source: VitroScan